SynthesisEndocrine2026
Association between blood cell count inflammatory biomarkers and non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Synthesis in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-alcoholic fatty liver disease (NAFLD) is a prevalent liver disorder linked to insulin resistance, progressing from simple steatosis to more advanced stages such as non-alcoholic steatohepatitis (NASH) and cirrhosis. Inflammation plays a key role in the progression of NAFLD. Biomarkers like the Systemic Immune-Inflammation Index (SII), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) have emerged as potential non-invasive indicators of inflammation.
objectiveThis study aims to evaluate the association between blood cell count inflammatory biomarkers (SII, NLR, PLR, LMR) and NAFLD.
methodsA systematic review and meta-analysis were conducted in accordance with the PRISMA guidelines, with the protocol registered on PROSPERO (CRD42024601678). Studies were retrieved from PubMed, Google Scholar, ClinicalTrials.gov and Cochrane. Observational studies that reported on inflammatory biomarkers in NAFLD patients were included. Data extraction and quality assessment were done using the Newcastle-Ottawa Scale (NOS).
resultsThe Neutrophil-to-Lymphocyte Ratio (NLR) showed a marginal increase (SMD = 0.45, 95% CI: − 0.10 to 1.00), with significant heterogeneity (I² = 99.4%) and publication bias. Platelet-to-Lymphocyte Ratio (PLR) was significantly lower in NAFLD (SMD = − 0.38, 95% CI: − 0.72 to − 0.04), with high heterogeneity (I² = 99.8%) and potential bias. Lymphocyte-to-Monocyte Ratio (LMR) and Systemic Immune-Inflammation Index (SII) showed no significant differences.
conclusionNLR and PLR show promise as biomarkers for NAFLD, but further large-scale studies are needed to address heterogeneity and publication bias.
Indexed as
Identifiers
41533293What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.